Skip to main content
. 2019 Mar 7;34(10):e83. doi: 10.3346/jkms.2019.34.e83

Table 2. Comparison of the epidemiology and disease severity between the breakthrough and unvaccinated cases.

Variables Breakthrough cases (n = 869) Unvaccinated cases (n = 139) P value OR (95% CI)
Clinical symptoms, No. (%)a
Rash 865 (99.5) 139 (100.0) - -
Affected part of rash onset
Face and neck 333 (38.5) 56 (40.3)
Body 468 (54.1) 60 (43.2)
Arms and legs 64 (7.4) 23 (16.5)
Fever 294 (33.8) 51 (36.7) 0.510 0.888 (0.602–1.309)
Headache 63 (7.3) 14 (10.1) 0.245 0.975 (0.517–1.838)
Arthralgiab 10 (1.2) 0 (0.0) - -
Severity, No. (%)
Mild (< 50) 742 (85.4) 104 (74.8) 0.002 0.570 (0.365–0.890)
Moderate to severe (≥ 50) 127 (14.6) 35 (25.8) - -
Moderate (50–249) 114 (89.8) 32 (91.4)
Severe (≥ 250) 13 (10.2) 3 (8.6)

OR = odds ratio, CI = confidence interval.

aEvery clinical symptom was detected and recorded; bContinuity-adjusted χ2 test was used because one of the cell frequencies was equal to zero.